ZyVersa Therapeutics, Inc. Overview
Pro stress-test →ZyVersa Therapeutics is a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of inflammatory and renal diseases with high unmet medical needs. The company is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible market >$100 billion.
Strategic Profile
Pro stress-test →The company is currently advancing a therapeutic development pipeline with two proprietary technologies — Inflammasome ASC Inhibitor IC 100, targeting inflammasome-driven inflammatory diseases, and Cholesterol Efflux Mediator VAR 200 for treatment of kidney diseases. Management characterizes the next 18 months as transformative, with plans to file an IND in Q4-2026 for IC 100, followed by Phase 1 trial initiation in overweight healthy subjects, with a SAD Phase 1 read-out expected in Q1-2027.
Competitive Landscape
Pro stress-test →ZyVersa operates in the crowded inflammasome inhibitor and renal disease therapeutic spaces. IC 100 is positioned as the next evolution of inflammasome inhibitors with dual-action mechanism (inhibiting multiple inflammasomes and ASC specks), potentially differentiating it from NLRP3-only inhibitors. Direct competitors include larger biotech firms advancing inflammasome programs and established renal disease therapeutics companies.
Industry Context
ZyVersa Therapeutics, Inc. operates in Clinical-stage biopharmaceutical development.
Key facts
Founded: 2022 · Headquarters: Weston, US · Employees: N/A · Revenue: $0 · Market cap: N/A